Tricida Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
1T7
- Share Price
-
$0.10
- (As of Monday Closing)
Tricida General Information
Description
Tricida Inc is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal, or GI, tract. The primary area of focus is to slow the progression of chronic kidney disease through the treatment of metabolic acidosis.
Contact Information
Website
www.tricida.comCorporate Office
- 2108 North Street
- Suite 4935
- Sacramento, CA 95816
- United States
Corporate Office
- 2108 North Street
- Suite 4935
- Sacramento, CA 95816
- United States
Tricida Stock Performance
As of 23-Jan-2023, Tricida’s stock price is $0.10. Its current market cap is $6.27M with 58M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.10 | $0.12 | $0.10 - $13.52 | $6.27M | 58M | 4.63K | -$2.37 |
Tricida Financials Summary
As of 30-Sep-2022, Tricida has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 686,486 | 503,955 | 243,586 | 1,584,705 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (116,488) | (159,022) | (249,887) | (170,404) |
| Net Income | (133,912) | (176,566) | (264,791) | (176,813) |
| Total Assets | 93,879 | 168,506 | 351,685 | 371,826 |
| Total Debt | 207,995 | 141,544 | 210,433 | 68,229 |
Tricida Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tricida Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tricida Comparisons
Industry
Financing
Details
Tricida Competitors (33)
One of Tricida’s 33 competitors is Nascent Biotech, a Corporation company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nascent Biotech | Corporation | San Diego, CA | ||||
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Resverlogix | Corporation | Calgary, Canada | ||||
| Esperion Therapeutics | Private Equity-Backed | Ann Arbor, MI | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE |
Tricida Patents
Tricida Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023064357-A1 | Pharmaceutical compositions for the treatment of lithiasis disorders | Inactive | 13-Oct-2021 | ||
| JP-2024512296-A | Crosslinked poly(allylamine) polymer pharmaceutical composition | Active | 01-Mar-2021 | ||
| JP-2026102594-A | Crosslinked poly(allylamine) polymer pharmaceutical composition | Pending | 01-Mar-2021 | ||
| AU-2021431510-A1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | Pending | 01-Mar-2021 | ||
| JP-7828096-B2 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | Active | 01-Mar-2021 | C08F226/02 |
Tricida Signals
Tricida Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tricida ESG
Risk Overview
Risk Rating
Updated April, 30, 2023
40.26 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Tricida FAQs
-
When was Tricida founded?
Tricida was founded in 2013.
-
Where is Tricida headquartered?
Tricida is headquartered in Sacramento, CA.
-
What is the size of Tricida?
Tricida has 55 total employees.
-
What industry is Tricida in?
Tricida’s primary industry is Drug Discovery.
-
Is Tricida a private or public company?
Tricida is a Public company.
-
What is Tricida’s stock symbol?
The ticker symbol for Tricida is 1T7.
-
What is the current stock price of Tricida?
As of 23-Jan-2023 the stock price of Tricida is $0.10.
-
What is the current market cap of Tricida?
The current market capitalization of Tricida is $6.27M.
-
Who are Tricida’s competitors?
Nascent Biotech, Akebia Therapeutics, Resverlogix, Esperion Therapeutics, and Ayala Pharmaceuticals are some of the 33 competitors of Tricida.
-
What is Tricida’s annual earnings per share (EPS)?
Tricida’s EPS for 12 months was -$2.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process